361 related articles for article (PubMed ID: 31587329)
21. Autoantibody to MDM2: A potential serological marker of primary Sjogren's syndrome.
Liu Y; Liao X; Wang Y; Chen S; Sun Y; Lin Q; Shi G
Oncotarget; 2017 Feb; 8(9):14306-14313. PubMed ID: 28147328
[TBL] [Abstract][Full Text] [Related]
22. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
23. FOLICation: engineering approved drugs as potential p53-MDM2 interaction inhibitors for cancer therapy.
Patil SP
Med Hypotheses; 2013 Dec; 81(6):1104-7. PubMed ID: 24210632
[TBL] [Abstract][Full Text] [Related]
24. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
Zhao Y; Aguilar A; Bernard D; Wang S
J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
[TBL] [Abstract][Full Text] [Related]
25. MDM2 inhibition: an important step forward in cancer therapy.
Konopleva M; Martinelli G; Daver N; Papayannidis C; Wei A; Higgins B; Ott M; Mascarenhas J; Andreeff M
Leukemia; 2020 Nov; 34(11):2858-2874. PubMed ID: 32651541
[TBL] [Abstract][Full Text] [Related]
26. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
27. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
Shangary S; Wang S
Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
[TBL] [Abstract][Full Text] [Related]
28. MDM2 oncogene as a novel target for human cancer therapy.
Zhang ; Wang H
Curr Pharm Des; 2000 Mar; 6(4):393-416. PubMed ID: 10788589
[TBL] [Abstract][Full Text] [Related]
29. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future.
Wang W; Albadari N; Du Y; Fowler JF; Sang HT; Xian W; McKeon F; Li W; Zhou J; Zhang R
Pharmacol Rev; 2024 May; 76(3):414-453. PubMed ID: 38697854
[TBL] [Abstract][Full Text] [Related]
30. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
31. Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed.
Zanjirband M; Rahgozar S
Curr Drug Targets; 2019; 20(11):1091-1111. PubMed ID: 30947669
[TBL] [Abstract][Full Text] [Related]
32. MDM2 non-genotoxic inhibitors as innovative therapeutic approaches for the treatment of pediatric malignancies.
Tisato V; Norcio A; Voltan R; Celeghini C; Zella D; Secchiero P
Curr Med Chem; 2013; 20(17):2226-36. PubMed ID: 23458617
[TBL] [Abstract][Full Text] [Related]
33. MDM2 inhibitors for cancer therapy.
Vassilev LT
Trends Mol Med; 2007 Jan; 13(1):23-31. PubMed ID: 17126603
[TBL] [Abstract][Full Text] [Related]
34. The Roles of MDM2 and MDMX in Cancer.
Karni-Schmidt O; Lokshin M; Prives C
Annu Rev Pathol; 2016 May; 11():617-44. PubMed ID: 27022975
[TBL] [Abstract][Full Text] [Related]
35. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
[TBL] [Abstract][Full Text] [Related]
36. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.
Wang S; Zhao Y; Aguilar A; Bernard D; Yang CY
Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28270530
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-13: A promising therapeutic target for autoimmune disease.
Mao YM; Zhao CN; Leng J; Leng RX; Ye DQ; Zheng SG; Pan HF
Cytokine Growth Factor Rev; 2019 Feb; 45():9-23. PubMed ID: 30581068
[TBL] [Abstract][Full Text] [Related]
38. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
Weber L
Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
[TBL] [Abstract][Full Text] [Related]
39. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
40. A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018).
Skalniak L; Surmiak E; Holak TA
Expert Opin Ther Pat; 2019 Mar; 29(3):151-170. PubMed ID: 30822185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
